Targeted Analysis of Bispecific Antibody Trials
Through an in-depth analysis of clinical trials involving bispecific antibodies, we identified key firms actively working in this modality and provided at least two confirmed contacts for each. This highly targeted list allowed Coriolis Pharma to effectively identify new potential customers and explore additional offerings for their formulation services. The actionable insights from this analysis allowed the Coriolis BD team to enhance its outreach efforts, engage with high-potential clients, and expand its business opportunities in the bispecific antibody space.
